glp 1 antagonists GLP-1 receptor agonists show promise in treating substance use disorders Current Insights, Advantages and Challenges

The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity

The second developed approach, body roundness index (BRI), associates a persons shape phenotype with high-risk adiposity components and multiple health outcomes

(Graphic: Business Wire) Hims Hers has been collecting data on access challenges across GLP-1s since the beginning of September

Review of weight-loss therapy studies, dieting tips, fitness equipment, exercise routines, and more

This builds on what we already know: menopause fundamentally alters metabolism

Ideal Partner Profiles